Novel Regimen May Transform Pediatric Cystic Fibrosis Care
Unlocking Promising Treatments for Cystic Fibrosis: A New Era The recent phase 3 trial of the drug combination vanzacaftor-tezacaftor-deutivacaftor signals an exciting advancement in cystic fibrosis (CF) treatment for children aged 6-11. This revealing study, as published in The Lancet Respiratory Medicine, showcases promising outcomes by maintaining lung function while enhancing CFTR protein function. Here, … Read more